{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:54:31Z","timestamp":1776862471893,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T00:00:00Z","timestamp":1378944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10792-013-9852-1","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T12:05:17Z","timestamp":1378901117000},"page":"541-547","source":"Crossref","is-referenced-by-count":12,"title":["Subconjunctival bevacizumab in the impending recurrent pterygia"],"prefix":"10.1007","volume":"34","author":[{"given":"Sezin Akca","family":"Bayar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Kucukerdonmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Oner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonca A.","family":"Akova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,12]]},"reference":[{"key":"9852_CR1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","volume":"33","author":"I Bahar","year":"2008","unstructured":"Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A (2008) Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33:23\u201328","journal-title":"Curr Eye Res"},{"key":"9852_CR2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.mehy.2007.01.047","volume":"69","author":"H Hosseini","year":"2007","unstructured":"Hosseini H, Nejabat M, Khalili MR (2007) Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 69:925\u2013927","journal-title":"Med Hypotheses"},{"key":"9852_CR3","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2008.155291","volume":"93","author":"AM Mansour","year":"2009","unstructured":"Mansour AM (2009) Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol 93:864\u2013865","journal-title":"Br J Ophthalmol"},{"key":"9852_CR4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICO.0b013e31818d382d","volume":"28","author":"CC Teng","year":"2009","unstructured":"Teng CC, Patel NN, Jacobson L (2009) Effect of subconjunctival bevacizumab on primary pterygium. Cornea 28:468\u2013470","journal-title":"Cornea"},{"key":"9852_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0065-1281(96)80038-9","volume":"98","author":"L Kria","year":"1996","unstructured":"Kria L, Ohira A, Amemiya T (1996) Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem 98:195\u2013201","journal-title":"Acta Histochem"},{"key":"9852_CR6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/00003226-200110000-00013","volume":"20","author":"DH Lee","year":"2001","unstructured":"Lee DH, Cho HJ, Kim JT et al (2001) Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 20:738\u2013742","journal-title":"Cornea"},{"key":"9852_CR7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00003226-200307000-00015","volume":"22","author":"J Jin","year":"2003","unstructured":"Jin J, Guan M, Sima J et al (2003) Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 22:473\u2013477","journal-title":"Cornea"},{"key":"9852_CR8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ophtha.2005.01.023","volume":"112","author":"M Gebhardt","year":"2005","unstructured":"Gebhardt M, Mentlein R, Schaudig U et al (2005) Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 112:1023\u20131030","journal-title":"Ophthalmology"},{"key":"9852_CR9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2006.02.026","volume":"113","author":"P Prabhasawat","year":"2006","unstructured":"Prabhasawat P, Tesavibul N, Leelapatranura K et al (2006) Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 113:1102\u20131109","journal-title":"Ophthalmology"},{"key":"9852_CR10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0161-6420(95)30770-1","volume":"102","author":"JA Cardillo","year":"1995","unstructured":"Cardillo JA, Alves MR, Ambrosio LE et al (1995) Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. Ophthalmology 102:1949\u20131952","journal-title":"Ophthalmology"},{"key":"9852_CR11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","volume":"35","author":"H Hosseini","year":"2007","unstructured":"Hosseini H, Nejabat M, Mehyar M et al (2007) Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 35:745\u2013748","journal-title":"Clin Exp Ophthalmol"},{"key":"9852_CR12","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"F Bock","year":"2007","unstructured":"Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545\u20132552","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9852_CR13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","volume":"91","author":"RP Manzano","year":"2007","unstructured":"Manzano RP, Peyman GA, Khan P et al (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804\u2013807","journal-title":"Br J Ophthalmol"},{"key":"9852_CR14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","volume":"27","author":"TI Kim","year":"2008","unstructured":"Kim TI, Kim SW, Kim S et al (2008) Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 27:349\u2013352","journal-title":"Cornea"},{"key":"9852_CR15","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","volume":"245","author":"M Erdurmus","year":"2007","unstructured":"Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577\u20131579","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"9852_CR16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/ICO.0b013e3181e16d67","volume":"30","author":"MR FallahTafti","year":"2011","unstructured":"FallahTafti MR, Khosravifard K, Mohammadpour M et al (2011) Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea 30:127\u2013129","journal-title":"Cornea"},{"key":"9852_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","volume":"28","author":"PC Wu","year":"2009","unstructured":"Wu PC, Kuo HK, Tai MH et al (2009) Topical bevacizumab eyedrops for limbal-conunctival neovascularization in impending recurrent pterygium. Cornea 28:103\u2013104","journal-title":"Cornea"},{"key":"9852_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","volume":"35","author":"MR Fallah","year":"2010","unstructured":"Fallah MR, Khosravi K, Hashemian MN et al (2010) Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 35:17\u201322","journal-title":"Curr Eye Res"},{"key":"9852_CR19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/ICO.0b013e3182151e0e","volume":"31","author":"K Lekhanont","year":"2012","unstructured":"Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P (2012) Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium. Cornea 31:155\u2013161","journal-title":"Cornea"},{"key":"9852_CR20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0161-6420(97)30197-3","volume":"104","author":"P Prabhasawat","year":"1997","unstructured":"Prabhasawat P, Barton K, Burkett G et al (1997) Comparison of conjunctival autografts, amniotic membrane grafts and primary closure for pterygium excision. Ophthalmology 104:974\u2013985","journal-title":"Ophthalmology"},{"key":"9852_CR21","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e31820ca63f","volume":"30","author":"A Shenasi","year":"2011","unstructured":"Shenasi A, Mousavi F, Shoa-Ahari S, Rahmi-Ardabili B, Fouladi RF (2011) Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea 30:1219\u20131222","journal-title":"Cornea"},{"key":"9852_CR22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","volume":"27","author":"I Bahar","year":"2008","unstructured":"Bahar I, Kaiserman I, McAllum P et al (2008) Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27:142\u2013147","journal-title":"Cornea"},{"key":"9852_CR23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","volume":"145","author":"M Papathanassiou","year":"2008","unstructured":"Papathanassiou M, Theodossiadis PG, Liakaros VS et al (2008) Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145:424\u2013431","journal-title":"Am J Ophthalmol"},{"key":"9852_CR24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","volume":"87","author":"IC You","year":"2009","unstructured":"You IC, Kang IS, Lee SH, Yoon KC (2009) Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 87:653\u2013658","journal-title":"Acta Ophthalmol"},{"key":"9852_CR25","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","volume":"247","author":"Y Koenig","year":"2009","unstructured":"Koenig Y, Bock F, Horn F et al (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375\u20131382","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"9852_CR26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/ICO.0b013e318160d019","volume":"27","author":"V Hurmeric","year":"2008","unstructured":"Hurmeric V, Mumcuoglu T, Erduman C et al (2008) Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 27:357\u2013362","journal-title":"Cornea"},{"key":"9852_CR27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0161-6420(94)31270-X","volume":"101","author":"LW Hirst","year":"1994","unstructured":"Hirst LW, Sebban A, Chant D (1994) Pterygium recurrence time. Ophthalmology 101:755\u2013758","journal-title":"Ophthalmology"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-013-9852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-013-9852-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-013-9852-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:30:31Z","timestamp":1559262631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-013-9852-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,12]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["9852"],"URL":"https:\/\/doi.org\/10.1007\/s10792-013-9852-1","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,12]]}}}